Getting to the Core of It All: Nanocapsules to Mitigate Infusion Reactions Can Promote Hemostasis and Be a Platform for Intravenous Therapies

Files

PU hNPs v4.pdf (1.12 MB)

Links to Files

https://pubs.acs.org/doi/full/10.1021/acs.nanolett.1c02746

Permanent Link

https://doi.org/10.1021/acs.nanolett.1c02746
 http://hdl.handle.net/11603/23390

Collections

UMBC Chemical, Biochemical & Environmental Engineering Department
UMBC Biological Sciences Department
UMBC College of Engineering and Information Technology Dean's Office
UMBC Faculty Collection
UMBC Student Collection

Author/Creator

Author/Creator ORCID

https://orcid.org/0000-0002-9208-5077
 https://orcid.org/0000-0002-0644-744X

Date

2021-10-29

Type of Work

journal articles
preprints
Text

Department

Program

Citation of Original Publication

Maisha, Nuzhat et al.; Getting to the Core of It All: Nanocapsules to Mitigate Infusion Reactions Can Promote Hemostasis and Be a Platform for Intravenous Therapies; Nano Letters, 21, 21, 9069–9076, 29 October, 2021; https://doi.org/10.1021/acs.nanolett.1c02746

Rights

This document is the unedited Author’s version of a Submitted Work that was subsequently accepted for publication in Nano Letters, copyright © American Chemical Society after peer review. To access the final edited and published work see https://doi.org/10.1021/acs.nanolett.1c02746.
This item is likely protected under Title 17 of the U.S. Copyright Law. Unless on a Creative Commons license, for uses protected by Copyright Law, contact the copyright holder or the author.

Subjects

Abstract

One of the significant challenges to translation of intravenously administered nanomaterials has been complement-mediated infusion reactions which can be lethal. Slow infusions can reduce infusion reactions, but slow infusions are not always possible in applications like controlling bleeding following trauma. Thus, avoiding complement activation and infusion responses is essential to manage bleeding. We identified nanocapsules based on polyurethane as candidates that did not activate C5a and explored their PEGylation and functionalization with the GRGDS peptide to create a new class of hemostatic nanomaterials. Using the clinically relevant rotational thromboelastography (ROTEM), we determined that nanocapsules promote faster clotting than controls and maintain the maximum clot firmness, which is critical for reducing bleeding. Excitingly, these polyurethane-based nanocapsules did not activate complement or the major pro-inflammatory cytokines. This work provides critical evidence for the role of modulating the core material in developing safer nanomedicines for intravenous applications.